Biotechnology News

– Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol — – FDA agreed that a single pivotal Phase 3...

Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions...

WAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway...

Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end...

SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene” or the “Company”), today announced the appointment of Matt Robbins, an experienced life sciences attorney with...

MINNEAPOLIS, July 07, 2026 (GLOBE NEWSWIRE) -- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes (T2D), announced that the ReCET...

TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh)...

Oral prolonged-release ketamine formulation (KET01) demonstrates minimal dissociation and cardiovascular effects with early antidepressant efficacy signals in treatment-resistant depressionResults...

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical...

GLASGOW, Scotland, July 07, 2026 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EnteroBiotix”), a clinical-stage biopharmaceutical company developing orally delivered full-spectrum microbiome...